Ameluz® is the name of Biofrontera’s first prescription drug to be made available on the market. It was approved in the EU in December 2011 for use in photodynamic therapy (PDT) of precancerous skin lesions (actinic keratosis). During PDT, a chemical reaction is triggered as a result of illumination with a strong red light, treating the diseased area of skin.
After being developed under the name BF-200 ALA, NOMEN developed the name Ameluz®. The two name components “ame-” derived from the French word “aimer” for love, and “luz”, derived from the Spanish word for light, alludes to the photodynmaic therapy (PDT).